Grigoriu Bogdan-Dragos, Grégoire Marc, Chahine Bachar, Scherpereel Arnaud
Inserm U774, Institut Pasteur, Lille, France.
Bull Cancer. 2008 Feb;95(2):177-84. doi: 10.1684/bdc.2008.0576.
The increasing number of malignant pleural mesothelioma (MPM) is a serious public health problem. The prognosis of this tumor is poor and most of the patients are diagnosed late in the disease's course when curative treatment is no more an option. It is therefore necessary to diagnose earlier MPM in these patients in order to obtain a potential significant improvement in survival. Some serum markers have been previously proposed for MPM diagnosis but none had sufficient sensitivity and specificity for being use in routine. Recently, soluble mesothelin and osteopontin have been proposed as diagnostic markers for mesothelioma. The authors reviewed recent data concerning the utility of these two molecules in the diagnosis and the treatment of MPM. Mesothelin seems to be a specific marker for the epithelioid subtype of mesothelioma. Despite a good sensitivity, osteopontin has a low specificity for mesothelioma diagnosis. However, there is not enough data yet to propose guidelines on the use of these markers in a day to day practice.
恶性胸膜间皮瘤（MPM）病例数的不断增加是一个严重的公共卫生问题。这种肿瘤的预后很差，大多数患者在疾病进程晚期才被诊断出来，此时已无法进行根治性治疗。因此，有必要对这些患者更早地诊断出MPM，以便显著提高生存率。此前曾提出一些血清标志物用于MPM诊断，但没有一种标志物在敏感性和特异性上足以用于常规检测。最近，可溶性间皮素和骨桥蛋白被提议作为间皮瘤的诊断标志物。作者回顾了有关这两种分子在MPM诊断和治疗中的效用的最新数据。间皮素似乎是间皮瘤上皮样亚型的特异性标志物。尽管骨桥蛋白敏感性良好，但在间皮瘤诊断中特异性较低。然而，目前尚无足够数据来提出在日常实践中使用这些标志物的指南。
